SYNAIRGEN PLC LS-,01

Synairgen has convened a general meeting for 8 September 2026 at which shareholders will vote on initiating a Members’ Voluntary Liquidation. The board has stated that both the company and its subsidiary Synairgen Research Limited remain solvent; the sole asset is the inhaled interferon‑beta treatment SNG001. A circular with background information, the proposed resolution and voting instructions will be sent to shareholders by post and email; the announcement follows a prior notice on 31 July 2026 regarding an orderly wind‑down. » More on de.investing.com

Synairgen announces completion of winding-down activities, identifies SNG001 as its sole asset, discontinues non-clinical R&D, closes sites and settles personnel and financial matters. A liquidation circular with a proposed resolution and notice of general meeting is due to be sent by the end of August 2026; the general meeting is planned for September 2026. After shareholder approval the voluntary liquidation will be initiated, a first interim payment is expected in October 2026 and a final distribution in H1 2027; the company anticipates total distributions of more than £5 million, subject to completion costs and advisory fees. » More on de.investing.com

Synairgen has begun preparations for a voluntary liquidation by its shareholders after the early termination of the Phase‑2 INVENT study. The study was stopped because patient recruitment fell far short of expectations; only 11 patients received a dose in the safety cohort, and no safety issues were observed. Synairgen sought buyers or licensees worldwide but did not enter into substantial due‑diligence processes with any party. An insolvency practitioner has been appointed; a timetable for circulars, shareholder resolutions, the start of liquidation and the first distribution is expected in the third quarter. » More on de.investing.com